Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000950170-25-083271
Filing Date
2025-06-06
Accepted
2025-06-06 17:30:19
Documents
1
Period of Report
2025-06-05

Document Format Files

Seq Description Document Type Size
1 4 ownership.html 4  
1 4 ownership.xml 4 3939
  Complete submission text file 0000950170-25-083271.txt   5351
Mailing Address BAARERSTRASSE 14 ZUG V8 CH-6300
Business Address BAARERSTRASSE 14 ZUG V8 CH-6300 6173154600
CRISPR Therapeutics AG (Issuer) CIK: 0001674416 (see all company filings)

EIN.: 473173478 | State of Incorp.: V8 | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address C/O CRISPR THERAPEUTICS AG 610 MAIN STREET CAMBRIDGE MA 02139
Business Address
Fleming Harold Edward (Reporting) CIK: 0001857250 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-37923 | Film No.: 251032161